US biotech company BiomeSense has announced the close of its oversubscribed $3 million (£2.4 million) funding round.
The round was led by Bluestein Ventures, the financing includes new investor Harvest Ridge Capital along with participation from existing investors SOSV and Seerave Foundation,
The new financing will support BiomeSense’s commercial launch, expected within the year.
BiomeSense Co-Founder and CEO, Kevin Honaker, said:
“Multiple studies have shown the microbiome is the portal to overall health and wellness, including the ability to predict a person’s response to a particular medicine and helping patients better manage conditions such as diabetes or celiac disease.
“While we know these possibilities exist, data barriers have blocked the industry from fully harnessing the microbiome’s potential.
“Now, thanks to our funders’ confidence, we can launch our technology and access the microbiome’s full precision medicine promise.”
BiomeSense is developing dedicated tools to help fully unlock microbiome precision medicine.
Its “smart bathroom” technology, GutLab, and bioinformatics platform, MetaBiome, aim to make generating and analysing large-scale, time-series microbiome datasets both possible and cost-effective.
BiomeSense is partnering with scientists to deploy the platform across a range of clinical studies to create the industry’s first curated time-series microbiome database.
This resource ‘will set new standards for microbiome precision medicine, from basic research through commercial product development,’ the company said in a press release.
Andrew Bluestein, Managing Partner at Bluestein Ventures and BiomeSense board director, said:
“As an early investor in BiomeSense, we have always believed deeply in the company’s vision to unlock personalised nutrition via the gut microbiome.
“The company has made immense progress since our initial investment, and we are proud to support BiomeSense as it enters this critical commercialisation phase.
“There is a significant measurement gap in the industry and the expected benefits from BiomeSense’s technology are enormous.”
Healthcare innovators and leaders honoured at Imprivata HealthCon user group and awards ceremony
Wearable communication system may reduce digital health divide
Molecule trains the immune system to prevent cancer
Diabetes patients urged to use fitness games with caution
Urgent work needed to tackle ‘substantial’ digital health inequality
eSight: “The technology has the potential to change someone’s life”
Microsoft invests £2.5 billion in UK AI
TMS shows promise in tackling depression ‘epidemic’
AI depression app set for NHS clinical trial
UK Biobank releases world’s largest single set of sequencing data
- Diagnostics4 weeks ago
3D model will advance understanding of spinal injury pathology
- Opinion1 week ago
Why it’s time to revisit workplace mental health initiatives and make them work for everyone
- AI3 weeks ago
AI can help predict survival outcomes for cancer patients
- Research5 days ago
Tackling the diagnostic testing sustainability problem